// App-Quantinova.ai

5194 : A Mouse-Human co-clinical trial with patient-derived xenograft (PDX) models demonstrates a predictive signature for dovitinib (TKI258), an FGFR and VEGFR inhibitor,in lung squamous cell carcinomalung cancer (LSCC)

Researchers

Presenter

  • Hye Ryun Kim

Principal Investigators

  • Han Na Kang

  • Sung Moo Kim

  • Hwan Kim

  • Kyoung-Ho Pyo

  • Myung-Ju Ahn

  • Tae Min Kim

  • Byoung Chul Cho

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Fibroblast growth factor receptor

  • Kinase Insert Domain Receptor

Drug/Treatment

  • Dovitinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved